IC
IMUX icon

Ikarian Capital’s Immunic IMUX Stock Holding History

Ikarian Capital’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,150
Closed -$213K – 133
2022
Q2 		$213K Hold
6,150
– – 0.04% 119
2022
Q1 		$696K Buy
+6,150
New +$712K 0.09% 113

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Ikarian Capital's IMUX Position: Q2 2026 in Review

Ikarian Capital reduced its Immunic (IMUX) stake by 0% in Q2 2026, selling an estimated $25 and leaving 67,464 shares worth $1.04M. The position accounts for 0.11% of the portfolio, ranked #103.

Ikarian Capital first reported a position in IMUX in Q2 2022 and has held it in 15 quarters since. The position peaked at $2.13M in Q1 2024. 56 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Ikarian Capital held 67,464 shares of Immunic worth $1.04M as of Q2 2026.
  • Ikarian Capital sold 2 Immunic shares in Q2 2026, an estimated $25.
  • Immunic made up 0.11% of Ikarian Capital's portfolio in Q2 2026, its #103 holding.
  • Ikarian Capital first reported a position in Immunic in Q2 2022 and has held it in 15 quarters since.
  • Ikarian Capital's Immunic position peaked at $2.13M in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.